RecruitingOBSERVATIONAL

Optical Genome Mapping in Hematological Malignancies

This research study is exploring a new and advanced genetic test called 'optical genome mapping' for people who might have blood cancers. These cancers include conditions like Myelodysplastic Syndromes (MDS), Leukaemia (ALL), and other related blood disorders. The main goal is to find out how useful this new genetic mapping technique is in helping doctors diagnose these conditions more accurately and efficiently. By looking closely at a person's genetic material, scientists hope to gain a clearer picture of these diseases, which could lead to better and faster ways to understand and manage them for patients in the future. Anyone with suspected blood cancer could potentially be included.

At a glance

Status

Recruiting

Sponsor

University Hospital, Brest

Enrolment target

200

Start

01 Sep 2021

Estimated completion

01 Sep 2026

MDS ALL Other Hematologic Malignant Neoplasms

What is this study about?

This study is all about trying a new, very detailed genetic test for people who have or might have a blood cancer. Blood cancers include conditions like leukaemia (where the body makes too many abnormal white blood cells) and myelodysplastic syndromes (MDS), which affect how your blood cells grow in the bone marrow. The new test, called 'optical genome mapping,' is a way to look very closely at your DNA – the instruction book inside every one of your cells.

Think of your DNA as a long string of beads. Sometimes, in blood cancers, these beads can be in the wrong order, or some might be missing or extra. Traditional tests can often spot these changes, but optical genome mapping is like having a super-magnifying glass that can see even tiny changes across the entire string of DNA. The researchers want to see if this detailed view can help them make a diagnosis faster and more precisely than current methods.

The main aim is to understand if using this new test can improve how doctors diagnose these types of cancers. If it proves to be really helpful, it could mean that in the future, patients get a quicker and more accurate diagnosis, which is really important for getting the right treatmentplan in place.

Key takeaways

Exploring a new advanced gene test for blood cancers.
Aims to improve diagnosis for conditions like leukaemia and MDS.
Uses samples already collected for routine care; no extra tests needed.
Participation helps future patients, though not your immediate care.
Open to both adults and children with suspected or diagnosed blood cancers.

Who may be eligible?

This study is open to both children and adults of any age. You might be able to take part if you have a suspected blood cancer or have already been diagnosed with one. This means your doctor has either sent a sample for testing in the genetics lab because they suspect a blood condition, or you already know you have a blood cancer.

To join, you or your legal guardian (if you're under 16) must agree to participate in the study. This usually involves signing a consent form after a doctor or nurse has explained everything to you.

However, you won't be able to join the study if you're under court-ordered protection or if you simply don't wish to take part. Your decision will always be respected.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you a child or an adult?
Do you have suspected blood cancer?
Have you already been diagnosed with a blood condition?
Are you able and willing to give your consent to participate?

Answer every question to see your result.

What does participation involve?

This study focuses on analyzing samples that are already being collected as part of your standard medical care, such as blood or bone marrow samples. You won't need to undergo any extra procedures specifically for this study.

The main thing involved is providing your consent for your already collected samples to be used for this special genetic testing. There are no additional visits, specific medications to take, or follow-up appointments required beyond your usual medical care for your condition. The researchers will simply use a part of your sample for the optical genome mapping test. The total duration of your 'participation' for the study itself would mainly be the time it takes to give your consent.

Potential risks and benefits

There are no direct medical risks from taking part in this study, as it uses samples that are already collected for your routine care and doesn't involve any new procedures or medications. The main benefit is that the information learned from your sample could help researchers understand blood cancers better, potentially leading to improved diagnostic methods for future patients. There won't be any direct benefit to you personally, as the results of this specific research test won't be given back to you or used to guide your immediate treatment. You are always free to change your mind and withdraw from the study at any time without it affecting your medical care.

Locations (4)

CHRU de Brest
Verified postcode
Brest, France· Recruiting
CH Morlaix, service d'hémato clinique
Verified postcode
Morlaix, France· Recruiting
CHIC, service d'hémato clinique
Verified postcode
Quimper, France· Recruiting
CH St Brieuc, service d'hémato clinique
Verified postcode
Saint-Brieuc, France· Recruiting

Common questions

What is 'optical genome mapping'?

It's a very advanced genetic test that can look at your entire set of genetic instructions (DNA) in great detail to find tiny changes.

Will this test change my treatment?

No, the results from this research test won't directly affect your current medical treatment or diagnosis. It's for research purposes only.

Do I need extra tests if I join?

No, you won't need any additional blood tests or procedures. The study will use samples already collected as part of your normal medical care.

Who can participate in this study?

Both children and adults suspected of having, or already diagnosed with, certain blood cancers can join, as long as they agree to take part.

What type of blood cancers are they looking at?

They are looking at various types, including conditions like leukaemia (ALL), myelodysplastic syndromes (MDS), and other related blood conditions.

How to find out more

Marie-Bérengère, TROADEC, PhD

marie-berengere.troadec@chu-brest.fr (33)230338055 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.